The US FDA approval of Fresenius Kabi’s Tyenne®, the first Tocilizumab biosimilar with both intravenous and subcutaneous formulations, is a breakthrough in bringing high-quality, affordable,
With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count
Following up on our previous post on looming biosimilar approvals over Eylea®(Aflibercept), on March 4, Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, announced
Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of
Biosimilar medicine is a biologic product. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) define a biosimilar product with certain
Regeneron and Bayer’s blockbuster drug, Aflibercept (Eylea®) gained its first approval in the US and the EU for Neovascular (Wet) Age-Related Macular Degeneration (AMD) in
